Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study
- 15 January 2020
- journal article
- research article
- Published by Elsevier BV in The Lancet. Respiratory Medicine
- Vol. 8 (6), 561-572
- https://doi.org/10.1016/s2213-2600(19)30267-x
Abstract
No abstract availableFunding Information
- Novartis Pharmaceuticals Corporation
- Novartis Institutes for BioMedical Research
- National Medical Research Council (NMRC/CSA/007/2016, NMRC/TCR/007-NCC/2013)
This publication has 26 references indexed in Scilit:
- Cancer Genomics: Diversity and Disparity Across Ethnicity and GeographyJournal of Clinical Oncology, 2016
- Adaptive Dose-Finding Studies: A Review of Model-Guided Phase I Clinical TrialsJournal of Clinical Oncology, 2014
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted DrugsJAMA, 2014
- The quest to overcome resistance to EGFR-targeted therapies in cancerNature Medicine, 2013
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingNature Biotechnology, 2013
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR MutationsJournal of Clinical Oncology, 2013
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung CancersClinical Cancer Research, 2013
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR InhibitorsScience Translational Medicine, 2011
- Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitorsOncogene, 2009
- Critical aspects of the Bayesian approach to phase I cancer trialsStatistics in Medicine, 2008